RUXOLITINIB
ruxolitinib 5 mg tablet, 56
RUXOLITINIB (13239T)
13239T
Manner of administration:Oral
Restriction (Streamlined authority code: 13911)
Indication: Grade II to IV acute graft versus host disease (aGVHD)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 0 | DPMQ: $2,305.13 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Jakavi | |||||